Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accumulated Expenses (2019 - 2025)

Eton Pharmaceuticals' Accumulated Expenses history spans 7 years, with the latest figure at $9.1 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 18893.75% year-over-year to $9.1 million; the TTM value through Sep 2025 reached $9.1 million, up 18893.75%, while the annual FY2024 figure was $8.9 million, 65.5% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $9.1 million at Eton Pharmaceuticals, up from $7.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.1 million in Q3 2025 and bottomed at $22000.0 in Q2 2021.
  • The 5-year median for Accumulated Expenses is $3.7 million (2022), against an average of $4.1 million.
  • The largest annual shift saw Accumulated Expenses tumbled 99.33% in 2024 before it skyrocketed 18893.75% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2021, then soared by 168.08% to $3.7 million in 2022, then skyrocketed by 47.08% to $5.4 million in 2023, then soared by 65.5% to $8.9 million in 2024, then rose by 2.28% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Accumulated Expenses are $9.1 million (Q3 2025), $7.5 million (Q2 2025), and $7.5 million (Q1 2025).